- Home
- KPRX vs MGRX Comparison
KPRX vs MGRX Comparison
Compare KPRX & MGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPRX | MGRX |
|---|---|---|
| Founded | 1998 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 8.5M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | KPRX | MGRX |
|---|---|---|
| Price | $2.09 | $0.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 40.6K | ★ 5.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $615,873.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.76 | $0.34 |
| 52 Week High | $4.18 | $5.33 |
Technical Indicators
Market Signals| Indicator | KPRX | MGRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 52.68 |
| Support Level | $2.01 | $0.52 |
| Resistance Level | $2.23 | $0.69 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 50.00 | 51.70 |
Price Performance
Historical ComparisonAbout KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.